This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
trusted source
proofread
Epstein-Barr virus associated tumors and drug repurposing
A new study published in OMICS: A Journal of Integrative Biology identified differentially expressed host and viral microRNAs (miRNAs) in six Epstein-Barr virus (EBV) associated tumors. The study reports several drug candidates for repurposing and targeting EBV latent infection: Glyburide, Levodopa, Nateglinide, and Stiripentol, among others.
The authors, Anamika Thakur and Manoj Kumar, Ph.D., from the Institute of Microbial Technology, Council of Scientific and Industrial Research (CSIR), Chandigarh, India, note: "This is the first integrative analysis, to the best of our knowledge, in regard to the potential therapeutic targets and drug repurposing candidates against the EBV tumors." EBV is associated with several types of malignancies, such as gastric carcinoma, Burkitt lymphoma, nasopharyngeal carcinoma, and Hodgkin's lymphoma.
"Epstein-Barr virus is a major planetary health burden especially in the oncology clinic. The study makes a contribution toward antiviral drug innovation for treatment of EBV infection and prevention of EBV-related tumors," says Vural Özdemir, MD, Ph.D., DABCP, Editor-in-Chief of OMICS.
More information: Anamika Thakur et al, Integration of Human and Viral miRNAs in Epstein-Barr Virus-Associated Tumors and Implications for Drug Repurposing, OMICS: A Journal of Integrative Biology (2023). DOI: 10.1089/omi.2023.0005
